Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
Earnings call Fluidra reported 7% constant FX sales growth and 9% EBITDA growth in FY2025, with notable market share gains and robust aftermarket performance. Management guides for 3%-7% sales growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results